新型NKCC1抑制剂STS66减轻小鼠缺血性脑卒中脑损伤
本研究在正常血压和血管紧张素II诱导的高血压C57BL/6J小鼠中,比较了布美他尼(BMT)、其亲脂性前药STS5及新型NKCC1抑制剂STS66对缺血性脑损伤的疗效。共206只小鼠随机接受溶媒DMSO、BMT、STS5或STS66治疗。结果显示,卒中后BMT、STS5或STS66治疗均使短暂性大脑中动脉闭塞后正常血压小鼠的梗死体积和脑肿胀减少约40%至50%,但STS66组生存率和感觉运动功能恢复更优,而STS5增加死亡率;在高血压小鼠永久性远端大脑中动脉闭塞模型中,STS66同样减轻梗死和神经功能缺损。
要点
- STS66减少短暂性大脑中动脉闭塞小鼠的梗死体积和脑肿胀约40%至50%。
- STS66较BMT和STS5改善生存率及感觉运动功能恢复,STS5增加死亡率。
- 高血压合并永久性局灶性脑缺血时,STS66减轻梗死和神经功能缺损。
核心结论
- 新型NKCC1抑制剂STS66在减少大血管短暂性缺血性脑卒中及高血压合并永久性局灶性缺血性脑卒中的梗死、肿胀和神经功能缺损方面优于BMT和STS5。
研究设计与样本
- 研究纳入206只C57BL/6J小鼠,随机接受溶媒DMSO、BMT、STS5或STS66治疗。
- 正常血压小鼠采用50分钟大脑中动脉闭塞再灌注诱导短暂性缺血性脑卒中。
- 血管紧张素II诱导的高血压小鼠采用永久性闭塞大脑中动脉远端分支诱导永久性局灶性缺血性脑卒中。
主要发现
- 正常血压小鼠短暂性大脑中动脉闭塞后,BMT、STS5或STS66治疗均使梗死体积和脑肿胀减少约40%至50%。
- STS66治疗组小鼠生存率和感觉运动功能恢复优于BMT或STS5组,而STS5治疗增加死亡率。
- 血管紧张素II诱导的高血压小鼠在永久性远端大脑中动脉闭塞后,SPAK和NKCC1磷酸化激活增加,梗死和神经功能缺损加重。
临床怎么用
- STS66可能作为缺血性脑卒中尤其是合并高血压患者的潜在神经保护剂,但需进一步临床研究验证。
局限性
- 研究仅在小鼠模型中进行,尚未在人体中验证疗效和安全性。
- 未报告STS66的剂量效应关系及长期功能结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Inhibition of brain NKCC1 (Na+-K+-Cl- cotransporter 1) with bumetanide (BMT) is of interest in ischemic stroke therapy. However, its poor brain penetration limits the application. In this study, we investigated the efficacy of 2 novel NKCC1 inhibitors, a lipophilic BMT prodrug STS5 (2-(Dimethylamino)ethyl 3-(butylamino)-4-phenoxy-5-sulfamoyl-benzoate;hydrochloride) and a novel NKCC1 inhibitor STS66 (3-(Butylamino)-2-phenoxy-5-[(2,2,2-trifluoroethylamino)methyl]benzenesulfonamide), on reducing ischemic brain injury. Methods- Large-vessel transient ischemic stroke in normotensive C57BL/6J mice was induced with 50-min occlusion of the middle cerebral artery and reperfusion. Focal, permanent ischemic stroke in angiotensin II (Ang II)-induced hypertensive C57BL/6J mice was induced by permanent occlusion of distal branches of middle cerebral artery. A total of 206 mice were randomly assigned to receive vehicle DMSO, BMT, STS5, or STS66. Results- Poststroke BMT, STS5, or STS66 treatment significantly decreased infarct volume and cerebral swelling by ≈40% to 50% in normotensive mice after transient middle cerebral artery occlusion, but STS66-treated mice displayed better survival and sensorimotor functional recovery. STS5 treatment increased the mortality. Ang II-induced hypertensive mice exhibited increased phosphorylatory activation of SPAK (Ste20-related proline alanine-rich kinase) and NKCC1, as well as worsened infarct and neurological deficit after permanent distal middle cerebral artery occlusion. Conclusions- The novel NKCC1 inhibitor STS66 is superior to BMT and STS5 in reducing ischemic infarction, swelling, and neurological deficits in large-vessel transient ischemic stroke, as well as in permanent focal ischemic stroke with hypertension comorbidity.
引用
- Huang H, Bhuiyan MIH, Jiang T, et al. A Novel Na+-K+-Cl- Cotransporter 1 Inhibitor STS66* Reduces Brain Damage in Mice After Ischemic Stroke. Stroke. 2019. PMID: 30862257. doi:10.1161/STROKEAHA.118.024287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。